GLUE

4.73

2.60% 0.12

Handel nachbörslich: 4.73

Monte Rosa Therapeutics Inc (GLUE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt GLUE? Forum Prognose

Schlusskurs vom Vortag:

$4.61

Offen:

$4.61

24-Stunden-Volumen:

298.48K

Relative Volume:

0.46

Marktkapitalisierung:

$312.47M

Einnahmen:

Nettoeinkommen (Verlust:

$-130.41M

KGV:

-2.1116

EPS:

-2.24

Netto-Cashflow:

$-67.76M

1W Leistung:

-0.84%

1M Leistung:

+5.11%

6M Leistung:

-33.47%

1J Leistung:

+31.75%

1-Tages-Spanne:

$4.585

$4.835

1-Wochen-Bereich:

$4.42

$4.835

52-Wochen-Spanne:

$3.5001

$12.40

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Firmenname

Monte Rosa Therapeutics Inc

Sektor

Healthcare (1166)

Branche

Biotechnology (655)

Telefon

617-949-2643

Adresse

321 HARRISON AVENUE, BOSTON

Mitarbeiter

134

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

GLUE's Discussions on Twitter

Vergleichen Sie GLUE mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GLUE Monte Rosa Therapeutics Inc	4.73	312.47M	0	-130.41M	-67.76M	-2.24
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-19	Herabstufung	Wells Fargo	Overweight → Equal Weight
2024-02-15	Eingeleitet	Wedbush	Outperform
2023-01-03	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-10-13	Eingeleitet	UBS	Buy
2022-08-15	Eingeleitet	Jefferies	Buy
2022-04-28	Eingeleitet	Credit Suisse	Neutral
2022-02-10	Eingeleitet	Wells Fargo	Equal Weight
2021-10-14	Eingeleitet	SVB Leerink	Mkt Perform

Alle ansehen

Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten

Jun 14, 2025

Monte Rosa gets FDA clearance to begin testing MRT-8102 - MSN

Jun 14, 2025

Jun 12, 2025

FMR LLC Reduces Stake in Monte Rosa Therapeutics Inc. - GuruFocus

Jun 12, 2025

Bank of America Corp DE Reduces Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Jun 12, 2025

Jun 11, 2025

Monte Rosa’s molecular glue degrader MRT-8102 gains IND clearance for inflammatory conditions - BioWorld MedTech

Jun 11, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Boosted by Millennium Management LLC - Defense World

Jun 11, 2025

Jun 10, 2025

Monte Rosa advances novel inflammatory disease treatment By Investing.com - Investing.com South Africa

Jun 10, 2025

Monte Rosa Therapeutics Says US FDA Accepts Investigational New Drug Application for MRT-8102 - marketscreener.com

Jun 10, 2025

Monte Rosa Therapeutics, Inc. Announces FDA Clearance of IND Application for MRT-8102, A NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - MarketScreener

Jun 10, 2025

Monte Rosa Therapeutics Announces FDA Clearance Of Ind Application For Mrt-8102 - MarketScreener

Jun 10, 2025

Monte Rosa Therapeutics Announces FDA Clearance of IND - GlobeNewswire

Jun 10, 2025

FDA Clearance: Monte Rosa's Revolutionary NEK7 Drug Could Transform Inflammatory Disease Treatment - Stock Titan

Jun 10, 2025

Jun 09, 2025

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet - sharewise

Jun 09, 2025

Jun 08, 2025

Two Sigma Advisers LP Takes $180,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Jun 08, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Sold by Jane Street Group LLC - Defense World

Jun 08, 2025

Squarepoint Ops LLC Takes Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Jun 08, 2025

Jun 04, 2025

6,231 Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Acquired by BNP Paribas Financial Markets - Defense World

Jun 04, 2025

ProShare Advisors LLC Buys New Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Jun 04, 2025

Jun 03, 2025

Deutsche Bank AG Buys 6,633 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Jun 03, 2025

Jun 02, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Purchased by Two Sigma Investments LP - Defense World

Jun 02, 2025

May 28, 2025

CDK2 degradation inducers disclosed in Monte Rosa patent - BioWorld MedTech

May 28, 2025

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire

May 28, 2025

Monte Rosa CEO Reveals Latest Molecular Glue Degrader Progress at Major Healthcare Conference - Stock Titan

May 28, 2025

May 27, 2025

Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and Aptose Biosciences (NASDAQ:APTO) - Defense World

May 27, 2025

May 26, 2025

D. E. Shaw & Co. Inc. Raises Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

May 26, 2025

May 25, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Holdings Increased by Northern Trust Corp - Defense World

May 25, 2025

May 24, 2025

Revenues Working Against Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Share Price Following 26% Dive - simplywall.st

May 24, 2025

May 16, 2025

Dimensional Fund Advisors LP Has $1.01 Million Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

May 16, 2025

May 15, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Increased by Tower Research Capital LLC TRC - Defense World

May 15, 2025

May 10, 2025

Results: Monte Rosa Therapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st

May 10, 2025

May 09, 2025